This approach has found some success both experimentally (targeting EAE triggered by myelin oligodendrocyte glycoprotein or proteolipid protein with myelin basic protein (MBP)-specific Tregs [143,144]) and in clinical trials (targeting Crohn’s disease with polyclonal ovalbumin-specific Tregs, in conjunction with dietary supplementation of ovalbumin to enable Tregs to activate at the inflamed gut membrane [145]). The gene discussed is MBP; the disease is Crohn disease.